Aadi Bioscience, Inc. (AADI)

Market Cap	122.84M
Revenue (ttm)	21.54M
Net Income (ttm)	-61.58M
Shares Out	24.52M
EPS (ttm)	-2.40
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	218
Open	5.01
Previous Close	5.01
Day's Range	4.90 - 5.05
52-Week Range	4.90 - 14.77
Beta	0.13
Analysts	Strong Buy
Price Target	45.00 (+798.2%)
Earnings Date	Nov 8, 2023

About AADI

Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus bound to albumin. The company is also involved in evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. Aadi Bioscience, Inc. was incorporated in 2007 and is he...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2011
• Employees: 89
• Stock Exchange: NASDAQ
• Ticker Symbol: AADI

Financial Performance

In 2022, AADI's revenue was $15.22 million, an increase of 1258.57% compared to the previous year's $1.12 million. Losses were -$60.51 million, -45.35% less than in 2021.

Analyst Forecast

According to one analyst, the rating for AADI stock is "Strong Buy" and the 12-month stock price forecast is $45.0.

Price Target

$45.0

(798.20% upside)

Analyst Consensus: Strong Buy